| Identification of the Domain of Plasmodium falciparum Erythrocyte Membrane Protein (PfEMP1) that Mediates Adhesion to Chondroitin Sulfate A |
Plasmodium falciparum malaria is more severe in pregnant women and causes disease in the mother and fetal death, even in those women who were previously immune. Severe malaria during pregnancy is more common during the first pregnancy (primigravida) and much less after multiple pregnancies (multigravid). Pregnant women are infected by parasites that sequester in the placenta and such sequestration contributes to growth retardation, infant... More ...
|
| Identification of New Malaria Parasite Erythrocyte Binding Protein (BAEBL) that Binds to Human Red Cells |
Malaria is endemic in many parts of the world, particularly in tropical regions such as Asia, Central America and South America. Recent estimates of the number of cases of malaria worldwide are between five hundred million and one billion. There are approximately two to three hundred million new cases of malaria each year and malaria causes a minimum of one million deaths each year. This invention relates to the identification and characteriza... More ...
|
| Peptidomimetic Inhibitors of Cathepsin D and Plasmepsins I and II |
The invention relates to the design and synthesis of linear and cyclic inhibitors of cathepsin D and plasmepsins I and II. The present invention also relates to the uses of these inhibitors for inhibiting invasion and metastasis of cancerous cells. It also covers the use of cathepsin D and plasmepsin I and II inhibitors for the prevention and treatment of Alzheimer's disease and malaria.... More ...
|
| Novel Antimalarial Compounds, Methods of Synthesis Thereof, Pharmaceutical Compositions Comprising Same, and Methods of Using Same for Treatment and Prevention of Malaria |
According to data recently reported by the World Health Organization (WHO), the death rate from malaria exceeds one million individuals per year. The Public Health Service seeks exclusive or non-exclusive licensee(s) to develop and commercialize the technology claimed within the portfolio of U.S. patents issued and pending, and corresponding international patents issued and pending. These patents and pending applications claim an exceptionally ... More ...
|
| Antimalarial Korupensamines And Pharmaceutical Compositions And Medical Uses Thereof |
The class of compounds known as korupensamines exhibit in vitro and in vivo antimalarial activity and offer a potent new means for treating and controlling this devastating disease. As many as 2-3 million people worldwide die from malaria each year, and many more suffer from long-term chronic infection. The deadliest malarial parasites have become resistant to previously effective antimalarial drugs such as chloroquine and other clinically useful... More ...
|
| Antimalarial Napthylisoquinoline Alkaloids And Pharmaceutical Compositions And Medicinal Uses Thereof |
This invention provides new napthylisoquinoline alkaloid compounds, and compositions and methods of use of known and new napthylisoquinoline alkaloids, for treatment or prevention of malaria. Some compounds of this class occur naturally in plant species of the Ancistrocladaceae and Dioncophyllaceae plant families which are found in tropical Africa and southern and southeast Asia. The compounds exhibit effective antimalarial properties and offer i... More ...
|
| Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria |
Malaria is one of the 5 major diseases of the world and a leading cause of childhood death in sub-Saharan Africa. Furthermore, the economic devastation of the disease is measured in the billions of dollars of lost wages and lowered productivity for the endemic areas of the world. In the US, it is a concern of travelers as well the military having to serve in those parts of the world. To date, there is no vaccine and one is not expected for anot... More ...
|
| Chondroitin Sulphate A Binding Domains: Potential Vaccine for Malaria |
The subject invention is related to a potential vaccine against malaria, and in particular to a vaccine that can prevent malaria infection in pregnant women. The invention relates to the identification of chondroitin sulphate A (CSA) binding domains in var2CSA homologs from different parasite strains. Malaria in pregnancy is a serious complication associated with the parasitized erythrocyte (PE) sequestration in the placenta. With successive p... More ...
|
| Binding Domains from Plasmodium vivax and Plasmodium falciparum Erythrocyte Binding Proteins
|
Despite considerable research efforts worldwide it has not been possible to design an effective vaccine against malaria. The present invention provides the basis for an effective vaccine against the blood state of malaria infections.
This invention relates to the identification of functional domains of Plasmodium proteins which play a role in erythrocyte binding and invasion. The inventors have identified the erythrocyte bind... More ...
|
| Target Antigens of Transmission Blocking Antibodies for Malaria Parasites
|
This invention is a continuation of U.S. Patent Application 07/912,294, which described Pfs28 a 28 kd protein found in Plasmodium gallinaceum. The new application describes a unique 28 kd protein expressed on the surface of ookinetes of Plasmodium falciparum (Pfs28). This protein is useful as a malaria transmission blocking vaccine. This technology contains claims to: the Pfs28 protein; Pfs28's amino acid and nucleic acid sequenc... More ...
|
| Synthetic Vaccine Against P. falciparum Malaria |
A synthetic vaccine is available for testing against P. falciparum malaria. Control of malarial disease has been achieved on a limited basis in certain parts of the world; however, no vaccine presently exists that can provide protective immunity. This synthetic vaccine contains a peptide which induces the activation of cytotoxic T cells that specifically recognize and kill cells infected with malaria sporozoites.
... More ...
|
| Transmission-Blocking Vaccine Against Malaria (2) |
A new immunovaccine directed against the Pfs25 antigen of Plasmodium falciparum offers to significantly enhance the development of an effective antimalarial vaccine. Previously, peptides derived from the sporozoite and asexual stage of the parasite have only been able to stimulate weak production of antibodies. This Pfs25 antigen, which is only expressed in the sexual reproductive stage of the parasite, stimulates strong antibody response; anti... More ...
|
| Transmission-Blocking Vaccine Against Malaria (1) |
A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells.
Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recogniz... More ...
|
| Recombinant DNA Clone Containing a Genomic Fragment of PfHRP-II Gene from Plasmodium falciparum |
A fragment of the PfHRP-II gene of Plasmodium falciparum was cloned using recombinant DNA techniques. This clone is capable of encoding PfHRP-II protein, a water-soluble, histidine-rich molecule that may be effective in the detection, diagnosis, and treatment of human malaria, which is caused by the parasite, P. falciparum. This protein may be particularly useful in the development of an anti-malaria vaccine. To date, no malaria vaccine has be... More ...
|
| Anti-Plasmodium Compositions and Methods of Use (E-049-2004) |
This invention describes methods and compositions of peptides that inhibit the binding of Plasmodium falciparum (P. falciparum) to erythrocytes. Malarial parasites enter the red blood cell through several erythrocyte receptors, each being specific for a given species of Plasmodia. For P. falciparum, the erythrocyte binding antigen (EBA-175) is the ligand of the plasmodia merozoites that interacts with the receptor gl... More ...
|
| Vaccines For Blocking Transmission of Plasmodium vivax
|
This invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible or... More ...
|
| Gene for Encoding a Human Malaria Vaccine Antigen |
Because chemical protection (chloroquine) and mosquito control have not adequately reduced deaths from malaria, especially in rural Africa, an anti-malaria vaccine is very desirable. Vaccines have been developed that protect against mosquito-induced infection of humans, which occurs in the sporozoitic stage of the life cycle of the parasite, Plasmodium falciparum. A vaccine may be prepared from the antigen of this invention that will pro... More ...
|
| Malarial Immunogen |
A new synthetic peptide, which stimulates secondary immune response to malaria circumsporozite (CS) protein, offers to improve the rational design and construction of more efficacious malaria vaccines. Previously prepared antimalarial vaccines have only been able produce secondary immune response in laboratory animals harboring particular genes. This new peptide sequence stimulates secondary helper T-cells as well as increased antibody productio... More ...
|
